Patient Willingness to Use Digital Health Technologies: A Quantitative and Qualitative Survey in Patients with Cancer Cachexia
Anil Tarachandani,Fikret Isik Karahanoglu,Andrew Messere,Lisa Tarasenko,Ann-Marie LaRonde-Richard,Nancy Kessler,Michelle Rossulek,Hans Plate,Kim Mahoney,Mar Santamaria
DOI: https://doi.org/10.2147/PPA.S396347
2023-04-28
Patient Preference and Adherence
Abstract:Anil Tarachandani, 1 Fikret Isik Karahanoglu, 1 Andrew Messere, 1 Lisa Tarasenko, 2 Ann-Marie LaRonde-Richard, 3 Nancy Kessler, 4 Michelle Rossulek, 3 Hans Plate, 5 Kim Mahoney, 5 Mar Santamaria 1 1 Early Clinical Development, Pfizer Inc., Cambridge, MA, USA; 2 Global Medical Affairs, Pfizer Inc., New York, NY, USA; 3 Internal Medicine Research Unit, Pfizer Inc., Cambridge, MA, USA; 4 Business Analytics and Insights, Pfizer Inc., New York, NY, USA; 5 Pensari LLC, Baltimore, MD, USA Correspondence: Mar Santamaria, Early Clinical Development, Pfizer Inc., 610 Main Street, Cambridge, MA, 02139, USA, Tel +1 617 852 5637, Fax +1 845 474 5357, Email Purpose: The objective of this study was to gain insights into the patients' perspectives on the impact of cancer cachexia on physical activity and their willingness to wear digital health technology (DHT) devices in clinical trials. Patients and Methods: We administered a quantitative 20-minute online survey on aspects of physical activity (on a 0– 100 scale) to 50 patients with cancer cachexia recruited through Rare Patient Voice, LLC. A subset of 10 patients took part in qualitative 45-minute web-based interviews with a demonstration of DHT devices. Survey questions related to the impact of weight loss (a key characteristic in Fearon's cachexia definition) on physical activity, patients' expectations regarding desired improvements and their level of meaningful activities, as well as preferences for DHT. Results: Seventy-eight percent of patients reported that their physical activity was impacted by cachexia, and for 77% of them, such impact was consistent over time. Patients perceived most impact of weight loss on walking distance, time and speed, and on level of activity during the day. Sleep, activity level, walking quality and distance were identified as the most meaningful activities to improve. Patients would like to see a moderate improvement of activity levels and consider it meaningful to perform physical activity of moderate intensity (eg, walk at normal pace) on a regular basis. The wrist was the preferred location for wearing a DHT device, followed by arm, ankle, and waist. Conclusion: Most patients reported physical activity limitations since the occurrence of weight loss compatible with cancer-associated cachexia. Walking distance, sleep and quality of walk were the most meaningful activities to moderately improve, and patients consider moderate physical activity as meaningful. Finally, this study population found the proposed wear of DHT devices on the wrist and around the waist acceptable for the duration of clinical studies. Keywords: physical activity, patients' expectations, meaningful activities, walking, DHT device As stated by the American Society of Clinical Oncology (ASCO) Cancer Cachexia Treatment Guidelines, cachexia is a multifactorial syndrome characterized by loss of appetite, weight, and skeletal muscle, leading to fatigue, functional impairment, increased treatment-related toxicity, poor quality of life, and reduced survival occurring in 30% of all cancer patients. 1,2 The definition of cachexia changed over time with early definitions concentrating on body weight, physical performance, and patient function. 2 The current diagnostic criterion for cachexia, agreed on by a panel of international experts through a Delphi consensus process in 2011, is weight loss >5% in 6 months, or weight loss >2% in individuals who are already depleted as evidenced by body mass index (BMI) <20 kg/m2 or skeletal muscle mass (sarcopenia). 3 To assess cachexia, the following domains should be considered: anorexia or reduced food intake, catabolic drive, muscle mass and strength, functional and psychosocial impairment. 3 Amongst the 21 symptoms present in the tailored MD Anderson Symptom Inventory (MDASI) tool, 4 lack of appetite, disturbed sleep, fatigue, lack of energy, and distress/feeling upset were the symptoms with the highest occurrence rates in cancer patients with cachexia. Moreover, patients with cachexia reported significantly higher severity scores than individuals without cachexia for the following categories of symptoms in the modified MDASI: pain, fatigue, disturbed sleep, lack of appetite, dry mouth, numbness, early satiety, diarrhea, anxiety, and lack of energy. 4 Symptoms extend to organs and tissues beyond muscles and adipose tissue, such as heart, liver and brain. 5 In addition to the symptoms described, physical inactivity has been documented in patients with cancer cachexia, eg, lung cancer patients with cachexia displayed ph -Abstract Truncated-
medicine, general & internal